Indaptus Therapeutics, Inc.(INDP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INDP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Indaptus Therapeutics, Inc. (INDP), a Healthcare sector company. INDP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Indaptus Therapeutics, Inc. reports net income of $-2.5M, free cash flow of $-7.0M. Top institutional holders of INDP by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, MORGAN STANLEY, based on the most recent SEC filings. INDP trades on the Nasdaq exchange and files with the SEC under CIK 1857044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INDP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Indaptus Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.5M
Free Cash Flow
Q1 2026
$-7.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-38.8% YoYOperating Income
-29.1% YoYEPS (Diluted)
+52.0% YoYTotal Assets
+26.9% YoYOp. Cash Flow
-20.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-20.8M -38.8% | $-15.0M +2.6% | $-15.4M -7.7% | $-14.3M -85.7% | $-7.7M -115.2% | $-3.6M |
| Operating Income | $-19.8M -29.1% | $-15.4M +6.2% | $-16.4M -9.8% | $-14.9M -92.9% | $-7.7M -114.7% | $-3.6M |
| EPS (Diluted) | $-21.58 +52.0% | $-44.96 -2356.8% | $-1.83 -5.8% | $-1.73 | — | — |
| Total Assets | $9.3M +26.9% | $7.3M -50.8% | $14.9M -46.8% | $28.1M -30.8% | $40.6M +2182.4% | $1.8M |
| Operating Cash Flow | $-14.8M -20.3% | $-12.3M +8.1% | $-13.4M -2.5% | $-13.1M -15.8% | $-11.3M -239.6% | $-3.3M |
AI Insight: INDP Financial Trends
Pre-revenue biotech burning $3–8M quarterly with equity base collapsing toward zero, signaling imminent funding pressure.
• Operating losses ranged $2–8M per quarter; Q1 2026 showed $2M op loss but $7M negative operating cash flow.
• Equity eroded from $6M (Q2 2024) to $1M (Q1 2026); briefly turned negative at $-2M (Q2 2025).
• No revenue reported across all eight quarters; company remains pre-commercialization.
⚠ Equity buffer at $1M leaves minimal runway before dilutive financing becomes unavoidable.
⚠ Q1 2026 operating cash burn ($7M) exceeded operating loss ($2M) by $5M—cash consumption accelerating.
AI Insight: INDP Ratio Trends
Insufficient data to assess trends — all financial ratios are blank across the entire nine-quarter period.
• No operating margin, net profit margin, return on equity, return on assets, return on invested capital, or debt-to-equity data available for analysis.
⚠ Complete absence of ratio data prevents evaluation of profitability, capital efficiency, or leverage trends through Q1 2026.
Get alerted when INDP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Indaptus Therapeutics, Inc. including:
Top Institutional Holders of INDP
CITADEL ADVISORS LLC
$71.0K39,018 shGEODE CAPITAL MANAGEMENT, LLC
$49.2K27,007 shMORGAN STANLEY
$4.9K2,697 shTower Research Capital LLC (TRC)
$3.4K1,890 shSBI Securities Co., Ltd.
$31.0017 shCWM, LLC
$4.002 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $71.0K | 39,018 |
| GEODE CAPITAL MANAGEMENT, LLC | $49.2K | 27,007 |
| MORGAN STANLEY | $4.9K | 2,697 |
| Tower Research Capital LLC (TRC) | $3.4K | 1,890 |
| SBI Securities Co., Ltd. | $31.00 | 17 |
| CWM, LLC | $4.00 | 2 |
More Healthcare Companies
View all Healthcare →Put INDP on your watchlist
Track score changes the day Indaptus Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INDP a good stock to buy?
13F Pro's AI-powered analysis of Indaptus Therapeutics, Inc. (INDP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INDP are available on the INDP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INDP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INDP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Indaptus Therapeutics, Inc.'s investment landscape.